Insights+: The US FDA New Drug Approvals in August 2023

Shots:The US FDA approved 10 NDAs and 3 BLA in August 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 89 novel products in 2023In August 2023, the major highlights drugs were Zurzuvae (zuranolone) approval for women with postpartum depression and Veopoz (pozelimab-bbfg) for children…

BySenior EditorSeptember 20, 2023

INSIGHTS+

Disease of the Month: Age-Related Macular Degeneration

Introduction:AMD, an eye disease that can cause of loss of eyesight/blur vision mostly in people ≥50 years of age and it is the leading cause of visual impairment worldwide.It occurs when the part of the retina (macula) is damaged. Patients lose their central vision and cannot see fine detailsThe three stages of…

BySenior EditorFebruary 9, 2023

VIEWPOINTS

Dr. Jeff Cleland, CEO & President at Ashvattha Therapeutics Shares his Views From First Patient Enrolled for the Treatment of AMD and DME

Shots:Jeff spoke about the first patient enrolled in a P-II study of D-4517.2 for the treatment of wet AMD and DMEJeff also talked about Ashvatta’s Hydroxyl Dendrimer Platform and how this technology is beneficial to treat AMD and DMEThe interview gives a profound understanding of how Ashvattha is developing hydroxyl dendrimer therapeutics…

BySenior EditorJanuary 3, 2023

Disease of the Month: Age-Related Macular Degeneration

Dr. Jeff Cleland, CEO & President at Ashvattha Therapeutics Shares his Views From First Patient Enrolled for the Treatment of AMD and DME

Contact US

OUR INFORMATION

FOLLW US

Insights+: The US FDA New Drug Approvals in August 2023

Disease of the Month: Age-Related Macular Degeneration

Dr. Jeff Cleland, CEO & President at Ashvattha Therapeutics Shares his Views From First Patient Enrolled for the Treatment of AMD and DME

FOLLW US

Sign Up to Our Newsletter